Difference between revisions of "Dutasteride (Avodart)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (8 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). | + | Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021319s014lbl.pdf Dutasteride (Avodart) package insert]</ref><ref>[[:File:Dutasteride.pdf | Dutasteride (Avodart) package insert (locally hosted backup)]]</ref><ref>[http://www.avodart.com Avodart manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021319s014lbl.pdf#page=26 Dutasteride (Avodart) package insert pages 26-29]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 11 | + | * 2001-11-20: Initial FDA approval for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland. |
| − | * | + | * 2011-06-09: New FDA Limitation of Use: AVODART is not approved for the prevention of prostate cancer. |
| − | + | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Avodart | *'''Brand name:''' Avodart | ||
| Line 25: | Line 25: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:5 alpha-reductase inhibitors]] | [[Category:5 alpha-reductase inhibitors]] | ||
Latest revision as of 01:01, 29 June 2024
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dutasteride (Avodart) package insert pages 26-29[1]
- Dutasteride (Avodart) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2001-11-20: Initial FDA approval for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland.
- 2011-06-09: New FDA Limitation of Use: AVODART is not approved for the prevention of prostate cancer.
Also known as
- Brand name: Avodart